LIVER BIOCHEMICAL CHANGES IN PATIENTS AFTER DIFFERENTIATED THYROID CANCER SURGERY AND BEFORE RADIOIODINE THERAPY

Objectives: To investigate liver enzyme changes and assess liver function in patients with differentiated thyroid cancer who have undergone surgery and are preparing for radioiodine therapy (131I therapy). Methods: A cross-sectional descriptive study on 163 patients with differentiated thyroid cancer 4 - 6 weeks after surgery at the Military Institute of Radiation Medicine and Oncology from April 2023 to April 2024. Evaluating liver enzymes and liver function at the time of preparing for 131I therapy, compared with a number of paraclinical parameters to find factors related to liver damage. Results: 38.0% of patients had liver damage (increased AST or ALT), of which 35.6% increased AST, and 24.5% increased ALT, mainly mildly increased (40 to < 100 U/L) and a low rate of liver dysfunction (5.5% slight increase in total Bilirubin and 11.0% decrease in Prothrombin ratio). Male gender and decreased FT4 concentration < 1.17 pmol/L were two factors related to liver damage with ORs of 2.56 and 2.74, respectively, p < 0.01. Conclusion: Liver damage is a relatively common phenomenon related to male gender and FT4 levels in patients with thyroid cancer after surgery and being prepared for 131I therapy.